Spironolactone
Product Images NDC 68151-2776

4 FDA label images from Carilion Materials Management · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 68151-2776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (68151 2776)

Label Image (68151 2776)
Label for Spironolactone 25 mg tablets manufactured by Actavis, with lot number 4415K141 and expiration date 01/16. The label includes a barcode and the product NDC code 68151-2776, indicating it is for prescription use only by Carilion Materials Management.*
FDA Label Image

01c355c2-figure-01 (Spironolactone Tablets 1)

01c355c2-figure-01 (Spironolactone Tablets 1)
Chemical structure diagram of spironolactone, showing its molecular framework and functional groups. The image includes rings, carbon chains, and specific substituents that characterize the spironolactone molecule.*
FDA Label Image

01c355c2-figure-02 (Spironolactone Tablets 2)

01c355c2-figure-02 (Spironolactone Tablets 2)
A survival probability curve chart comparing Spironolactone and placebo groups over time in months. The vertical y-axis represents probability, while the horizontal x-axis shows months from 0 to 48. Two lines depict the survival probabilities, with Spironolactone showing higher probability over time. The chart includes sample sizes and a statistical significance value (log-rank p < 0.001).*
FDA Label Image

01c355c2-figure-03 (Spironolactone Tablets 3)

01c355c2-figure-03 (Spironolactone Tablets 3)
A forest plot showing hazard ratios (HR) and 95% confidence intervals (CI) for various subgroups including age, sex, race, LVEF, heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The x-axis ranges from 0.2 to 1.4 with an indication of Spironolactone benefit on the left and placebo benefit on the right.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.